Status:
RECRUITING
Safety and Efficacy of Oral HX9428 Tablets in Subjects With Wet Age-related Macular Degeneration (wAMD)
Lead Sponsor:
Fujian Haixi Pharmaceuticals Co., Ltd.
Conditions:
Wet Age-related Macular Degeneration (AMD)
Eligibility:
All Genders
50-85 years
Phase:
PHASE1
PHASE2
Brief Summary
This study will evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of Oral HX9428 tablets in patients with wet age-related macular degeneration(wAMD)
Detailed Description
This is a Multicenter, Open-label, Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Oral HX9428 tablets in Subjects with Wet Age-related Macular Degeneration (wAMD). The study...
Eligibility Criteria
Inclusion
- Participants must meet the following criteria for study entry:
- Age ≥50 years and ≤80 years (Phase I), Age ≥50 years and ≤85 years (Phase II) at the time of signing informed consent, male or female;
- Active choroidal neovascularization (CNV) secondary to AMD, as evidenced on fluorescein fundus angiography (FFA) and optical coherence tomography (OCT) (Active CNV is defined as the presence of subretinal or intraretinal fluid or leakage); A total lesion size of \<12 disc areas on FFA ;
- Treatment-naive , or previous anti-VEGF treatment that was effective and discontinued for more than 3 months, with OCT evidence of subretinal fluid or cystoid macular edema;
- ETDRS BCVA 19 to 78 letters in the study eyes( corresponding to a Snellen equivalent of approximately 20/32 to 20/400) ;
- Other protocol-specified inclusion criteria may apply
Exclusion
- Subjects who meet any of the following criteria will be excluded from this study:
- Subjects diagnosed with polypoidal choroidal vasculopathy by Indocyanine Green(ICG) angiography who are at high risk of massive hemorrhage;
- On FFA/CFP: subretinal hemorrhage of \>50 % of the total lesion area or that involves the fovea; fibrosis or atrophy of \>50 % of the total lesion area or that involves the fovea;
- CNV due to causes other than AMD;
- Any condition in the study eye that could compromise best-corrected visual acuity;
- Active ocular inflammation or infection in either eye or a history of idiopathic or autoimmune-related uveitis;
- Refractive error exceeding -6.00 D spherical equivalent;
- Ocular surgery performed in the study eye within 90 days before screening;
- Previous treatment with photodynamic therapy (within 120 days of screening), external-beam radiotherapy, macular laser photocoagulation, macular surgery, or transpupillary thermotherapy;
- Systemic anti-VEGF therapy administered within 90 days before the first dose;
- Pregnant or lactating women;
- Known hypersensitivity or contraindication to any study-related procedure drugs;
- History of severe cardiac disease, symptomatic congestive heart failure, unstable angina, acute coronary syndrome, myocardial infarction, coronary revascularization, thrombotic event, or bleeding episode within 6 months prior to the start of study drug, uncontrolled hypertension (systolic blood pressure\> 150 mmHg and/or diastolic blood pressure \> 100 mmHg on optimal medical therapy), or ventricular arrhythmia requiring ongoing treatment;
- Stroke within 12 months or transient ischemic attack within 6 months of enrolment；
- Poorly controlled diabetes (HbA1c ≥ 12 %);
- Other protocol-specified exclusion criteria may apply.
Key Trial Info
Start Date :
July 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 7 2029
Estimated Enrollment :
198 Patients enrolled
Trial Details
Trial ID
NCT07185841
Start Date
July 1 2025
End Date
January 7 2029
Last Update
September 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Hospital
Beijing, China, 100010